Symptoms and General Pathology

All Conditions

Neoplasms

Blood and Lymph Conditions

Rare Diseases

Recurrence

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Disease Attributes

Neoplasms by Histologic Type

Hematologic Diseases

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Antineoplastic Agents

Antirheumatic Agents

All Drugs and Chemicals

Cyclophosphamide

Fludarabine

Fludarabine phosphate

Patients will receive a full dose CART infusion at day 0.

a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.

CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells

Hu Chen, M.D., Ph.D.

Bin Zhang, M.D., Ph.D.

Patients with acute myeloid leukemia(AML) recurred after the allogeneic hematopoietic stem cell transplantation (allo-HSCT) have a dismal prognosis.The investigators developed donor-derived chimeric antigen receptor modified-T cell(CART) to target CD123 for the treatment of AML. The investigators start the Phase I study aimed to treat recurred post-transplantation AML patients using donor-derived CAR-T. The purpose of this study is to assess the safety and effectiveness of anti-CD123 CAR-T cells in patients.

Allo-HSCT is increasingly being used for AML, however, leukemia relapse remain a main problem for decades.Recently the investigators have witnessed great progresses in cancer therapy with chimeric antigen receptors modified T cells(CAR-T), especially for B-cell malignance. preclinical data about anti-CD123 CART have shown raised serious safety concerns of human anti-CD123 CAR-T for severe impairment of normal hematopoiesis in NSG mice.Patients with AML recurred after allo-HSCT have a dismal prognosis.The investigators developed donor-derived CART to target CD123 for the treatment of AML. The investigators start the Phase I study aimed to recurred post-transplantation AML patients using donor-derived CAR-T. The purpose of this study is to assess the safety and effectiveness of anti-CD123 CAR-T cells in patients.

Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT

Donor-derived Anti-CD123 Chimeric Antigen Receptors Modified T Cells for Recurred Acute Myeloid Leukaemia After Allogeneic Hematopoietic Stem Cell Transplantation

Affiliated Hospital to Academy of Military Medical Sciences

Glioma

Neoplasms, Germ Cell and Embryonal

Astrocytoma

Neoplasms, Nerve Tissue

Neoplasms, Glandular and Epithelial

Oligodendroglioma

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Neuroepithelial

Neuroepithelioma

Vorasidenib

Servier Pharmaceuticals LLC

Jonathan Dewey, MD

This is an expanded access program to provide vorasidenib for treatment of patients 12 years or older with IDH1- or IDH2-mutated glioma.

This expanded access program is designed to provide access to vorasidenib for patients with IDH1- or IDH2-mutated glioma who are not eligible for other vorasidenib clinical trials, and who in the opinion of the treating oncologist would potentially benefit from treatment with vorasidenib.

Safety assessments (including vital signs, hematology, and serum chemistry) occur every two weeks for the first two cycles (28 day each cycle), then monthly for the duration of treatment. Treatment with vorasidenib will continue until, in the clinical judgement of the treating physician, the patient is no longer benefiting from the treatment, vorasidenib is approved and available by prescription, or the study is terminated.

Requests by treating physicians to file a single patient investigational new drug application as part of the expanded access program for vorasidenib will be considered on a case-by-case basis.

Vorasidenib Expanded Access Program

The Expanded Access Use of Vorasidenib in Patients With IDH1 or IDH2 Mutated Glioma

Servier Pharmaceuticals, LLC

Servier

Digestive System Diseases

Colorectal Neoplasms

Intestinal Diseases

Colonic Diseases

Colonic Neoplasms

Gastrointestinal Diseases

Gastrointestinal Neoplasms

Intestinal Neoplasms

Digestive System Neoplasms

Antipyretics

Anti-Inflammatory Agents

Fibrinolytic Agents

Analgesics

Platelet Aggregation Inhibitors

Herbal and Botanical

Aspirin

Anti-Inflammatory Agents, Non-Steroidal

Analgesics, Non-Narcotic

Cyclooxygenase Inhibitors

Enzyme Inhibitors

Cola

Patients treated with acetylsalicylic acid 80 mg once daily for 5 years. Patients will be stratified according to the admission of adjuvant chemotherapy.

Patients treated with placebo. Patients will be stratified according to the admission of adjuvant chemotherapy.

acetylsalicylic acid

Placebo

Marc Peeters, Prof dr

The purpose of this study is to determine whether acetylsalicylic acid is effective on the recurrence and survival of colon cancer patients.

The purpose of this study is to determine the effect of 80mg acetylsalicylic acid (given orally once daily for 5 years) on 5 year overall survival (OS) for stage II and III colon cancer patients of 45 years of age and older. Preclinical, epidemiologic and clinical evidence suggest that acetylsalicylic acid use may reduce overall cancer risk and mortality in colon cancer patients. It is a phase III double blind placebo controlled, randomized trial of adjuvant low-dose acetylsalicylic acid in colon cancer patients. Patients will be stratified at randomization by centre, age (\<70 and ≥70 years) chemotherapy use (any versus none) and disease stage.

ASPIRIN Trial Belgium

A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients

The time to an event for OS is defined as the time interval between the date of randomisation and the date of death.

The time to an event for DFS is defined as the time interval between the date of randomisation and the date of disease recurrence or death, whichever comes first. Recurrence of a disease can be a loco-regional recurrence, a distant recurrence or a new primary colon cancer. The evidence for recurrence must be documented in the patients' file.

The time elapsed between randomisation until treatment discontinuation due to disease progression, unacceptable toxicity, death or any other event of interest.

Kom Op Tegen Kanker

Anticancerfund

University Hospital, Antwerp

Prof. dr. Marc Peeters, Diensthoofd Oncologie

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT	NCT03114670	Adult Acute Mye...	CD123CAR-41BB-C...	18 Years -	Affiliated Hospital to Academy of Military Medical Sciences
Vorasidenib Expanded Access Program	NCT05592743	Glioma Recurrence Disease Attribu... Pathologic Proc... Neoplasms, Neur... Neuroectodermal... Neoplasms, Germ... Neoplasms by Hi... Neoplasms Neoplasms, Glan... Neoplasms, Nerv...	Vorasidenib	12 Years -	Servier
ASPIRIN Trial Belgium	NCT03464305	Colon Cancer	acetylsalicylic... Placebo	45 Years -	University Hospital, Antwerp
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT	NCT03114670	Adult Acute Mye...	CD123CAR-41BB-C...	18 Years -	Affiliated Hospital to Academy of Military Medical Sciences
Vorasidenib Expanded Access Program	NCT05592743	Glioma Recurrence Disease Attribu... Pathologic Proc... Neoplasms, Neur... Neuroectodermal... Neoplasms, Germ... Neoplasms by Hi... Neoplasms Neoplasms, Glan... Neoplasms, Nerv...	Vorasidenib	12 Years -	Servier

Spots Global Cancer Trial Database for disease attributes